4BB 4basebio Plc

 
TIDM4BB 
 
4basebio UK Societas 
 
                  ("4basebio", the "Company" or the "Group") 
 
             Admission to Trading on AIM and First Day of Dealings 
 
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on 
exploiting its intellectual property in the field of gene therapies and DNA 
vaccines, is pleased to announce the admission of its ordinary shares to 
trading on the AIM market of the London Stock Exchange. Dealings will commence 
at 8.00 a.m. today, Wednesday 17 February 2021, under the ticker 4BB 
(ISIN GB00BLD8ZL39). 
 
Upon Admission, the Company will have 12,317,473 ordinary shares in issue and a 
market capitalisation of approximately £14.5 million. 
 
Heikki Lanckriet, Chief Executive Officer of 4basebio, commented: 
 
"We are delighted to be admitted to AIM today. As a Cambridge based company 
with significant ambitions, we believe AIM is the ideal market to support our 
further development. We would also like to extend our thanks to our staff, 
advisors and shareholders who continue to support our ongoing growth strategy." 
 
Cairn Financial Advisers LLP is acting as Nominated Adviser to the Company and 
finnCap is acting as Broker. 
 
Company Highlights 
 
4basebio is a specialist life sciences group focused on therapeutic DNA for 
gene therapies and DNA vaccines and providing solutions for effective and safe 
delivery of these DNA based products to patients. It is the intention of the 
Company to become a market leader in the manufacture and supply of high purity, 
synthetic DNA for research, therapeutic and pharmacological use. The immediate 
objectives of 4bb are to validate and scale its DNA synthesis and advance its 
collaborations to facilitate the functional validation of its DNA based 
products and gene delivery solutions. 
 
The Company divested from 4basebio AG ("4bb AG"), a German company listed on 
the Prime Standard segment of the Frankfurt Stock Exchange, following the 
disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology 
business to AIM-quoted Abcam plc in January 2020 for ?120million. Following the 
disposal, 4bb AG retained its genomics business which owned and licensed 
certain intellectual property including its proprietary, patent-protected 
technology, TruePrimeT. This is the foundation for building the Company's 
synthetic DNA manufacturing business which 4bb AG transferred to the Company 
along with funding to continue the Company's development and investment. 
 
On Admission, the Company will have cash reserves of approximately £14.4million 
which the Directors consider will provide sufficient working capital for the 
development and scale-up of the business to commercialisation. 
 
The Company has a wholly-owned Spanish subsidiary, 4basebio S.L.U. ("4bb 
Spain") and a wholly-owned UK subsidiary, 4basebio UK Limited ("4bb UK") which 
in turn wholly-owns 4basebio Discovery Limited ("4bb Discovery"). 
 
4bb UK focuses on the DNA validation and scaling work required as a 
prerequisite to developing Good Manufacturing Practice ("GMP") grade DNA, 
suitable for use in gene therapies and DNA vaccines. It is expected that 4bb 
UK's operations will continue to expand as it becomes the Group's centre of 
large-scale production. 
 
4bb Discovery was created as a particle and indication research and development 
arm of the Group with the intention of developing intellectual property around 
non-viral delivery platforms. 
 
4bb Spain undertakes primary DNA synthesis research and is involved in the 
manufacture of enzymes used in the DNA manufacturing process as well as in 
other diagnostic and research applications. 
 
The Admission Document can be found on 4basebio's website: www.4basebio.com 
 
For further enquiries, please contact: 
 
4basebio UK Societas                                    +44 (0)12 2396 7943 
Heikki Lanckriet 
 
Nominated Adviser                                       +44 (0)20 7213 0880 
Cairn Financial Advisers LLP 
Jo Tuner / Sandy Jamieson 
 
Broker                                                  +44 (0)20 7220 0500 
finnCap Ltd 
Geoff Nash 
Richard Chambers/Charlotte Sutcliffe 
 
Caution regarding forward looking statements 
 
Certain statements in this announcement, are, or may be deemed to be, forward 
looking statements. Forward looking statements are identi?ed by their use of 
terms and phrases such as "believe", "could", "should" "envisage", 
"estimate", "intend", "may", "plan", "potentially", "expect", 
"will" or the negative of those, variations or comparable expressions, 
including references to assumptions. These forward-looking statements are not 
based on historical facts but rather on the Directors' current expectations and 
assumptions regarding the Company's future growth, results of operations, 
performance, future capital and other expenditures (including the amount, 
nature and sources of funding thereof), competitive advantages, business 
prospects and opportunities. Such forward looking statements re?ect the 
Directors' current beliefs and assumptions and are based on information 
currently available to the Directors. 
 
 
 
END 
 
 

(END) Dow Jones Newswires

February 17, 2021 02:00 ET (07:00 GMT)

4basebio (LSE:4BB)
Historical Stock Chart
From Mar 2024 to Apr 2024

4basebio (LSE:4BB)
Historical Stock Chart
From Apr 2023 to Apr 2024